Acquisition - December 22, 2015
Karo Bio acquires Allevo
Karo Bio acquires Allevo rights from Cederroth for SEK 60 mln. The company acquires rights to weight control product range Allevo from Cederroth for some 60 million Swedish crowns ($7 million). According to reuters Allevo yearly revenues is 62 million crowns. In order to finance the acquisition Karo Bio will use a short-term credit corresponding to the […]
Acquisition - November 2, 2015
Karo Bio acquires over 90% of MedCore
Karo Bio acquires more than 90 percent of the shares in MedCore AB, a company which primarily markets licensed medtech products to pharmacies and hospitals in the Nordic region. MedCore’s products target the therapeutic areas Diabetes, Anesthesia/Intensive Care and Surgery. Turnover is approx. MSEK 50 with an operating profit expected to be slightly positive in 2015. […]
Acquisition - October 5, 2015
Karo Bio acquires Swereco Group
Karo Bio AB has acquired the shares in Swereco Group. Swereco markets OTC products mainly to pharmacies or directly to health care providers. Net sales in 2014 were 150 MSEK. There are several well-established brands in the product portfolio. Mabs medical compression stockings have a leading market position in Sweden and accounts for over 40 […]
Acquisition - September 3, 2015
Karo Bio acquires Apropharm
Karo Bio io AB has announced today that it has acquired the two companies Apropharm AS and Apropharm AB. The product portfolio consists of mainly pharmaceutical products in Norway and Sweden. A newly registred product for soar throat, Triolif, has recently become registred and will be launched in September. The turnover is approximately 50 MSEK with a operating profit […]
Acquisition - April 27, 2015
Karo Bio Acquires Tanomed
Recently Karo Bio acquired 100 percent of the drug research company Tanomed AB for 20 MSEK. This deal gives Karo Bio access to Tanomed’s nasal spray to relieve and prevent the progression of the common cold by reinforcing the body’s own defenses, according to Biotech Umeå. The patented technology is based on Swedish research in […]
Clinical Trials - July 2, 2014
Karo Bio granted more Vinnova funding for cancer studies
Karo Bio has been granted another SEK 3.8 million from the Swedish innovation agency Vinnova for the preclinical development of an ERbeta agonist for the treatment of different forms of cancer. The financing is granted through the Forska & Väx program and will be paid out in stages during 2014 and early 2015, to finance studies within […]
